With interest, we read the article by Xiol et al. 1 regarding differences in serum measurements between different laboratories and their influence on the Model for End-Stage Liver Disease (MELD) and the Model for End-Stage Liver Disease incorporating serum sodium (MELD-Na). They reported significant
Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease–sodium scores determined at three university-based laboratories of the same area
✍ Scribed by Xavier Xiol; Pere Gines; Lluis Castells; Jorge Twose; Alba Ribalta; Xavier Fuentes-Arderiu; Santiago Rodriguez; Jose Castellote; Miquel Navasa; Roser Deulofeu
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 188 KB
- Volume
- 15
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21688
No coin nor oath required. For personal study only.
✦ Synopsis
The Model for End-Stage Liver Disease (MELD) score is considered an objective and reliable measure of liver disease severity. However, the use of specific laboratory methodologies may introduce significant and clinically relevant variations into the score. It has been suggested that the incorporation of sodium into MELD (MELD-Na) can provide a more accurate survival prediction than MELD alone. Before implementing organ allocation based on the MELD score in an area with 3 transplant centers, we studied whether there were significant variations in MELD and MELD-Na scores determined at each center. Seventy patients on the waiting list were studied simultaneously. Blood samples for each patient were divided into 3 aliquots and were processed in the 3 laboratories in order to calculate MELD and MELD-Na scores. There were statistical differences between the 3 laboratories in the MELD and MELD-Na scores and their parameters. The MELD score was identical in the 3 laboratories for only 6 of the 70 patients, and the MELD-Na score was identical for only 9. MELD and MELD-Na scores from 2 laboratories differed by 1 point or more in 54% and 47% of cases, respectively. Our study confirms that there is major variability in the MELD score, serum sodium, and MELD-Na score. These differences are clinically relevant, and in order to guarantee equitable organ allocation based on the MELD score, similar laboratory methodologies should be implemented at all centers in the same organ procurement area. Alternatively, the possibility of setting up a central laboratory in each organ procurement area should be considered.
📜 SIMILAR VOLUMES
We thank Garritsen et al. 1 for their interest in our article about differences in Model for End-Stage Liver Disease (MELD) and Model for End-Stage Liver Disease-Sodium (MELD-Na) scores determined at 3 different laboratories. 2 We agree that one of the important messages of our article is the import
Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not signific
Renal function has a significant impact on early mortality in patients with cirrhosis. However, creatinine and creatinine-based equations are inaccurate markers of renal function in cirrhosis. The aim of this study was to reassess correlations between creatinine-based equations and measured glomerul
Organ allocation based on Model for End-Stage Liver Disease (MELD) resulted in decreased waiting list mortality in the United States. However, reports suggest an increase in resource utilization as a consequence of this. The aim of this study is to assess the correlation of MELD at transplant with p
Cost issues in liver transplantation (LT) have received increasing attention, but the cost-utility is rarely calculated. We compared costs per quality-adjusted life year (QALY) from the time of placement on the LT waiting list to 1 year after transplantation for 252 LT patients and to 5 years after